| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
64,210,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
141 |
Avg
Vol: |
1,513,129 |
| 52
Week Range: |
$0.000001 - $0.238 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. is focused on advancing eganelisib (IPI-549), an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma. The preclinical findings indicate that eganelisib may have the potential to treat various solid tumors and represents an additive or synergistic approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. Further, preclinical studies showed that eganelisib inhibits the regrowth of tumors that can occur following treatment with chemotherapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
410,196 |
425,190 |
| Total Sell Value |
$0 |
$0 |
$28,714 |
$38,646 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
2 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Evnin Anthony B |
Director |
– • – |
2017-05-25 |
4 |
A |
$1.74 |
$20,000 |
D/D |
11,494 |
118,585 |
|
- |
|
| Berkowitz Jeffrey |
Director |
– • – |
2017-05-25 |
4 |
A |
$1.74 |
$10,000 |
D/D |
5,747 |
36,131 |
|
- |
|
| Smith Ian F |
Director |
– • – |
2017-05-25 |
4 |
A |
$1.74 |
$39,999 |
D/D |
22,988 |
22,988 |
|
- |
|
| Venuti Michael C |
Director |
– • – |
2017-03-17 |
4 |
S |
$3.48 |
$21,750 |
D/D |
(6,250) |
50,000 |
|
- |
|
| Kutok Jeffery |
Chief Scientific OfficerOffice |
• – – |
2017-02-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,072 |
|
- |
|
| Lampert Mark N |
Director |
– • • |
2017-01-03 |
4 |
B |
$1.34 |
$5,867 |
D/D |
4,379 |
2,339,083 |
3.84 |
- |
|
| Lampert Mark N |
Director |
– • • |
2016-12-30 |
4 |
B |
$1.34 |
$4,760 |
D/D |
3,553 |
2,335,849 |
3.84 |
- |
|
| Lampert Mark N |
Director |
– • • |
2016-12-28 |
4 |
B |
$1.34 |
$986,805 |
D/D |
738,848 |
698,623 |
3.92 |
- |
|
| Lampert Mark N |
Director |
– • • |
2016-12-20 |
4 |
B |
$1.35 |
$29,809 |
D/D |
22,001 |
621,547 |
3.92 |
- |
|
| Lampert Mark N |
Director |
– • • |
2016-12-19 |
4 |
B |
$1.36 |
$269,322 |
D/D |
198,264 |
619,303 |
3.92 |
- |
|
| Lampert Mark N |
Director |
– • • |
2016-12-16 |
4 |
B |
$1.28 |
$556,360 |
D/D |
434,656 |
598,282 |
3.92 |
- |
|
| Kango Sujay |
Chief Commercial Officer |
• – – |
2016-12-13 |
4 |
S |
$1.25 |
$63,259 |
D/D |
(49,991) |
599 |
|
- |
|
| Kango Sujay |
Chief Commercial Officer |
• – – |
2016-12-12 |
4 |
S |
$1.30 |
$32,612 |
D/D |
(25,009) |
50,590 |
|
- |
|
| Lampert Mark N |
Director |
– • • |
2016-12-02 |
4 |
B |
$1.19 |
$62,480 |
D/D |
52,500 |
550,470 |
3.92 |
- |
|
| Lampert Mark N |
Director |
– • • |
2016-12-01 |
4 |
B |
$1.18 |
$176,365 |
D/D |
148,894 |
547,554 |
3.92 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2016-11-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,065,714 |
|
- |
|
| Perkins Adelene Q |
Chief Executive Officer |
• • – |
2016-10-31 |
4/A |
A |
$0.00 |
$0 |
D/D |
85,800 |
449,220 |
|
- |
|
| Kango Sujay |
Chief Commercial Officer |
• – – |
2016-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
75,599 |
|
- |
|
| Perkins Adelene Q |
President & CEO |
• • – |
2016-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
85,800 |
447,411 |
|
- |
|
| Adams Julian |
President of R&D |
• – – |
2016-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
59,150 |
59,150 |
|
- |
|
| Tasker Seth A |
General Counsel |
• – – |
2016-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
8,917 |
8,917 |
|
- |
|
| Bloch Lawrence E |
EVP, CFO & CBO |
• – – |
2016-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
39,039 |
41,905 |
|
- |
|
| Tasker Seth A |
General CounselOfficer |
• – – |
2016-07-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,525 |
|
- |
|
| Evnin Anthony B |
Director |
– • – |
2016-06-17 |
4 |
A |
$1.52 |
$19,999 |
D/D |
13,157 |
107,091 |
|
- |
|
| Lander Eric S |
Director |
– • – |
2016-06-17 |
4 |
A |
$1.52 |
$9,999 |
D/D |
6,578 |
80,319 |
|
- |
|
227 Records found
|
|
Page 3 of 10 |
|
|
